Bio-Gene Technology 2023 Annual General Meeting Chairman's Address

Bio-Gene Technology Limited (ASX:BGT) reported significant progress in the development of novel insecticides during the 2023 Annual General Meeting. The Chairman, Alex Ding, highlighted the company's focus on addressing the global issue of increasing insecticide resistance and toxicity through the commercialization of their active ingredients Qcide and Flavocide.

Chairman's Commentary on Company Progress and Strategic Objectives

I would like to report on a year of significant progress and change for the Company, positioning Bio-Gene for the next pivotal stage of commercializing our active ingredients Qcide and Flavocide. Over the past twelve months, we have made good progress in developing the next generation of novel insecticides, collaborating with our global commercial and research partners to solve the global problem of increasing insecticide resistance. Current chemistry is no longer proving effective to control pests and disease-carrying vectors, while at the same time, the inhabitable environment for pests is growing due to changing weather patterns.

Summary of Bio-Gene Technology's Progress and Outlook

Bio-Gene Technology has made significant strides in the development of novel insecticides, aiming to address the global challenge of insecticide resistance and toxicity. The company's unique and naturally derived chemical compounds, Qcide and Flavocide, represent a breakthrough in public health insecticides after three decades. With the appointment of new executives and board members, Bio-Gene is strategically positioned to advance the commercialization of their key assets and strengthen their commercial capability. The company continues to receive strong validation from global partners and anticipates expanding commercial partnerships. Bio-Gene looks forward to updating shareholders as they progress in commercializing Qcide and Flavocide, aiming to provide effective pest control solutions while minimizing environmental impact.